全文获取类型
收费全文 | 1408437篇 |
免费 | 115626篇 |
国内免费 | 3329篇 |
专业分类
耳鼻咽喉 | 18360篇 |
儿科学 | 46547篇 |
妇产科学 | 41044篇 |
基础医学 | 200748篇 |
口腔科学 | 37696篇 |
临床医学 | 125979篇 |
内科学 | 284321篇 |
皮肤病学 | 33353篇 |
神经病学 | 116877篇 |
特种医学 | 53839篇 |
外国民族医学 | 464篇 |
外科学 | 210476篇 |
综合类 | 32756篇 |
现状与发展 | 3篇 |
一般理论 | 487篇 |
预防医学 | 109987篇 |
眼科学 | 31488篇 |
药学 | 98487篇 |
1篇 | |
中国医学 | 3347篇 |
肿瘤学 | 81132篇 |
出版年
2021年 | 10844篇 |
2019年 | 11661篇 |
2018年 | 16569篇 |
2017年 | 12668篇 |
2016年 | 14256篇 |
2015年 | 16000篇 |
2014年 | 22552篇 |
2013年 | 33383篇 |
2012年 | 45370篇 |
2011年 | 47909篇 |
2010年 | 28150篇 |
2009年 | 27040篇 |
2008年 | 44302篇 |
2007年 | 46808篇 |
2006年 | 47377篇 |
2005年 | 45846篇 |
2004年 | 43747篇 |
2003年 | 41684篇 |
2002年 | 40180篇 |
2001年 | 72998篇 |
2000年 | 74528篇 |
1999年 | 61556篇 |
1998年 | 16987篇 |
1997年 | 15430篇 |
1996年 | 15581篇 |
1995年 | 14788篇 |
1994年 | 13394篇 |
1993年 | 12582篇 |
1992年 | 45836篇 |
1991年 | 43477篇 |
1990年 | 41491篇 |
1989年 | 39553篇 |
1988年 | 36179篇 |
1987年 | 35355篇 |
1986年 | 32860篇 |
1985年 | 31281篇 |
1984年 | 23825篇 |
1983年 | 20023篇 |
1982年 | 12207篇 |
1981年 | 10780篇 |
1979年 | 20703篇 |
1978年 | 14578篇 |
1977年 | 12085篇 |
1976年 | 11365篇 |
1975年 | 11621篇 |
1974年 | 13990篇 |
1973年 | 13536篇 |
1972年 | 12637篇 |
1971年 | 11469篇 |
1970年 | 10911篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
151.
Ramya C. Mosarla Muthiah Vaduganathan Arman Qamar Javid Moslehi Gregory Piazza Robert P. Giugliano 《Journal of the American College of Cardiology》2019,73(11):1336-1349
Patients with active cancer are at an increased risk of arterial and venous thromboembolism (VTE) and bleeding events. Historically, in patients with cancer, low molecular weight heparins have been preferred for treatment of VTE, whereas warfarin has been the standard anticoagulant for stroke prevention in patients with atrial fibrillation (AF). More recently, direct oral anticoagulants (DOACs) have been demonstrated to reduce the risk of venous and arterial thromboembolism in large randomized clinical trials of patients with VTE and AF, respectively, thus providing an attractive oral dosing option that does not require routine laboratory monitoring. In this review, we summarize available clinical trial data and guideline recommendations, and outline a practical approach to anticoagulation management of VTE and AF in cancer. 相似文献
152.
153.
Toshiro Hara Rony Chanoch-Myers Nathan D. Mathewson Chad Myskiw Lyla Atta Lillian Bussema Stephen W. Eichhorn Alissa C. Greenwald Gabriela S. Kinker Christopher Rodman L. Nicolas Gonzalez Castro Hiroaki Wakimoto Orit Rozenblatt-Rosen Xiaowei Zhuang Jean Fan Tony Hunter Inder M. Verma Kai W. Wucherpfennig Itay Tirosh 《Cancer cell》2021,39(6):779-792.e11
- Download : Download high-res image (228KB)
- Download : Download full-size image
154.
155.
156.
157.
M. D. Wiles A. El-Nayal G. Elton M. Malaj J. Winterbottom C. Gillies I. K. Moppett K. Bauchmuller 《Anaesthesia》2022,77(2):143-152
Pulse oximetry is used widely to titrate oxygen therapy and for triage in patients who are critically ill. However, there are concerns regarding the accuracy of pulse oximetry in patients with COVID-19 pneumonitis and in patients who have a greater degree of skin pigmentation. We aimed to determine the impact of patient ethnicity on the accuracy of peripheral pulse oximetry in patients who were critically ill with COVID-19 pneumonitis by conducting a retrospective observational study comparing paired measurements of arterial oxygen saturation measured by co-oximetry on arterial blood gas analysis (SaO2) and the corresponding peripheral oxygenation saturation measured by pulse oximetry (SpO2). Bias was calculated as the mean difference between SaO2 and SpO2 measurements and limits of agreement were calculated as bias ±1.96 SD. Data from 194 patients (135 White ethnic origin, 34 Asian ethnic origin, 19 Black ethnic origin and 6 other ethnic origin) were analysed consisting of 6216 paired SaO2 and SpO2 measurements. Bias (limits of agreement) between SaO2 and SpO2 measurements was 0.05% (−2.21–2.30). Patient ethnicity did not alter this to a clinically significant degree: 0.28% (1.79–2.35), −0.33% (−2.47–2.35) and −0.75% (−3.47–1.97) for patients of White, Asian and Black ethnic origin, respectively. In patients with COVID-19 pneumonitis, SpO2 measurements showed a level of agreement with SaO2 values that was in line with previous work, and this was not affected by patient ethnicity. 相似文献
158.
159.
A. Montalto V. Piazza F. Albi R. Gherli C. Contento A. Palermo F. Musumeci 《Transplantation proceedings》2019,51(1):206-209
Background
Pump speed optimization in patients implanted with a ventricular assist device represents a major challenge during the follow-up period. We present our findings on whether combined invasive hemodynamic ramp tests and cardiopulmonary exercise testing (CPX) can help optimize patient management.Methods
Eighteen patients implanted with a HeartMate 3 (HM3) device underwent ramp tests with right heart catheterization (including central venous pressure [CVP], pulmonary artery pressure, pulmonary capillary wedge pressure [PCWP], and blood pressure) and echocardiography. Data were recorded at up to 4 speed settings. Speed changes were in steps of 200 revolutions/min (rpm). Evaluation of functional capacity by CPX was conducted according to the modified Bruce protocol.Results
Only 30% of patients had normal PCWPs at their original rpm settings. In going from lowest to highest speeds, cardiac output improved by 0.25 ± 0.35 L/min/step (total change, 1.28 ± 0.3 L/min), and PCWP decreased by 1.9 ± 0.73 mm Hg/step (total change, 6 ± 1.6 mm Hg). CVP and systolic blood pressure did not change significantly with rpm. The rpm assessment was adjusted based on test results to achieve CVPs and PCWPs as close to normal limits as possible, which was feasible in all patients. On CPX, all patients demonstrated good performance (peak VO2, 16.8 ± 3.5 mL/kg/min).Conclusion
Hemodynamic ramp testing provides an objective means of optimizing rpm, and has the potential to provide good exercise tolerance. 相似文献160.